1. Pharming will attend the Oppenheimer Rare Disease Summit on December 11. 2. Dr. Anurag Relan will speak about the HAE market. 3. The summit focuses on innovations in rare disease treatments. 4. Pharming is committed to developing medicines for rare and life-threatening conditions. 5. This participation may enhance investor interest in Pharming's initiatives.
FAQ
Why Bullish?
Participation in prominent conferences typically raises investor visibility and interest, positively impacting stock prices. Similar instances where biopharmaceutical companies gained attention at industry events have led to price increases.
How important is it?
The announcement highlights Pharming's engagement with key stakeholders in rare diseases, underlining its strategic positioning in the market.
Why Short Term?
The upcoming summit is immediate, with potential short-term stock price movements following presentations and news announcements.
Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases.
Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET / 19:50 CET.
To schedule a one-on-one meeting with Pharming's management team, please contact Investor Relations at investor@pharming.com or your Oppenheimer representative.
About Pharming Group N.V.
Pharming Group N.V. (NASDAQ:PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
Media Relations
Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: media.relations@pharming.com
U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038
Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27
Attachment
